Multiplex KRAS superRCA assays

Rarity offers ultra-sensitive and multiplexed mutation detection on 21 of the most common KRAS hotspot mutations for liquid biopsy research.

To see our Multiplex KRAS superRCA assays, and explore all our assays:

Analyzing KRAS mutations in cancer is crucial for understanding the underlying mechanisms of tumor growth. These mutations, prevalent in cancers like colorectal, lung, and pancreatic, drive uncontrolled cell proliferation.

The superRCA KRAS multiplex panel is also available in tumor oriented multiplex combinations with other genes, such as NRAS, PIK3CA, BRAF, and AKT1.

Additional variants available on request, reach out to us through this form and we will help you further!

Share this article

Recommended articles

Rarity Bioscience at the CYTO 2024 Conference

Rarity Bioscience’s Linus Bosaeus and Lei Chen was at the CYTO 2024 Conference in Edinburgh, to present the study Ultra-sensitive Molecular MRD on Flow Cytometer using superRCA Mutation Assay, showcasing our new ultra-sensitive mutation detection technology superRCA.

Read more »

Rarity Bioscience at the Nordic Precision Medicine Forum

Rarity Bioscience was at the Nordic Precision Medicine Forum, presenting an engaging study that highlights the latest advancements in precision oncology: ”Ultra-sensitive Monitoring of Minimal Residual Disease (MRD) for Cancer Patients, using superRCA Mutation Assays with Flow Cytometry Readout”

Read more »